Viking Therapeutics (VKTX) Retained Earnings (2016 - 2025)
Historic Retained Earnings for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to -$689.9 million.
- Viking Therapeutics' Retained Earnings fell 5246.39% to -$689.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$689.9 million, marking a year-over-year decrease of 5246.39%. This contributed to the annual value of -$487.9 million for FY2024, which is 2909.51% down from last year.
- Viking Therapeutics' Retained Earnings amounted to -$689.9 million in Q3 2025, which was down 5246.39% from -$599.1 million recorded in Q2 2025.
- Over the past 5 years, Viking Therapeutics' Retained Earnings peaked at -$182.2 million during Q1 2021, and registered a low of -$689.9 million during Q3 2025.
- For the 5-year period, Viking Therapeutics' Retained Earnings averaged around -$360.2 million, with its median value being -$330.8 million (2023).
- Per our database at Business Quant, Viking Therapeutics' Retained Earnings tumbled by 2806.12% in 2024 and then plummeted by 5246.39% in 2025.
- Viking Therapeutics' Retained Earnings (Quarter) stood at -$223.2 million in 2021, then crashed by 30.86% to -$292.0 million in 2022, then dropped by 29.41% to -$377.9 million in 2023, then fell by 29.1% to -$487.9 million in 2024, then tumbled by 41.4% to -$689.9 million in 2025.
- Its last three reported values are -$689.9 million in Q3 2025, -$599.1 million for Q2 2025, and -$533.5 million during Q1 2025.